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Abstract
Background and aims
Using mathematical modeling to illustrate and predict how different heroin source-forms:
“black tar” (BTH) and powder heroin (PH) can affect HIV transmission in the context of con-
trasting injecting practices. By quantifying HIV risk by these two heroin source-types we
show how each affects the incidence and prevalence of HIV over time. From 1997 to 2010
PH reaching the United States was manufactured overwhelmingly by Colombian suppliers
and distributed in the eastern states of the United States. Recently Mexican cartels that sup-
ply the western U.S. states have started to produce PH too, replacing Colombian distribution
to the east. This raises the possibility that BTH in the western U.S. may be replaced by PH
in the future.
Design
We used an agent-based model to evaluate the impact of use of different heroin formula-
tions in high- and low-risk populations of persons who inject drugs (PWID) who use different
types of syringes (high vs. low dead space) and injecting practices. We obtained model
parameters from peer-reviewed publications and ethnographic research.
Results
Heating of BTH, additional syringe rinsing, and subcutaneous injection can substantially
decrease the risk of HIV transmission. Simulation analysis shows that HIV transmission risk
may be strongly affected by the type of heroin used. We reproduced historic differences in
HIV prevalence and incidence. The protective effect of BTH is much stronger in high-risk
compared with low-risk populations. Simulation of future outbreaks show that when PH
replaces BTH we expect a long-term overall increase in HIV prevalence. In a population of
PWID with mixed low- and high-risk clusters we find that local HIV outbreaks can occur
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even when the overall prevalence and incidence are low. The results are dependent on evi-
dence-supported assumptions.
Conclusions
The results support harm-reduction measures focused on a reduction in syringe sharing and
promoting protective measures of syringe rinsing and drug solution heating.
Introduction
In addition to being a huge burden on society in terms of drug overdoses and deaths, inter-
twined opioid and heroin epidemics in the United States [1, 2] have the potential to increase
HIV transmission among people who inject drugs (PWID). Heroin use among American
adults increased almost fivefold between 2002 and 2013 [3]; most heroin is used by injection,
and among PWID the proportion of persons living with a diagnosis of HIV infection in 2010
was 0.0215 [4]. Among PWID, most HIV transmission is attributed to the sharing of needles
and syringes [5]; however, there is an intriguing difference in HIV prevalence among PWID in
the western (5%-6%) versus eastern United States (11%-12%) [6, 7]. A study of 96 U.S. cities
showed that in the late 1990s and early 2000s the difference was 2%-11% versus 3%-35% with
the mean in the western U.S. areas three times lower than that of the eastern states (3.6 vs. 9.4)
[8]. A similar relationship was observed in HIV incidence [9]. In most of the western U.S. cit-
ies HIV incidence was less than 1 per 100 person-years, but the mean incidence in the eastern
U.S. cities was over 3. Although a number of behavioral, environmental, historical, or struc-
tural factors may contribute to this disparity, we explore one plausible explanation based on
the geographic distribution and use of specific heroin source-forms [6].
Heroin varies in physical and chemical characteristics by production source [10]. To the
west of the Mississippi River heroin is mostly available as a solid form (i.e., Mexican-sourced
“black tar” [BTH]. “Powder heroin” (PH) is predominant east of the Mississippi River and
although the source is changing from Colombian to Mexican, heroin form remains predomi-
nantly the same: powder [2, 11]. Besides an ecological association between HIV prevalence,
incidence, and geographic prevalence of BTH (Fig 1), these contrasting source-forms vary in
physical state, cold/hot water solubility, pH, heat stability, weight/volume, and purity [6].
These chemical features could provide mechanistic insight into the factors associated with dif-
ferences in HIV incidence.
Heroin types, injecting practices, and HIV
HIV transmission can occur when a small amount of infected blood from a previous HIV-pos-
itive PWID remains in the syringe and enters the bloodstream of the next PWID. The striking
difference in virus survivability when different source-types of heroin (BTH vs. PH) are used
could substantially influence the probability of HIV transmission associated with heroin type
[12]. It has been thus hypothesized [6] that injection preparation practices associated with
these heroin types explain the higher prevalence of HIV among PWID in cities with more
prevalent PH versus more prevalent BTH. Despite some biological evidence that the virus does
not survive well in high temperatures, actual survival and consequent HIV transmission are
not well quantified for each individual injecting practice. In this study we attempted to identify
and quantify behavioral and mechanistic factors affecting HIV transmission, and to translate
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them into HIV incidence and prevalence. Several mechanistic factors affect virus survivability
[6]:
1. Heat. BTH is usually heated to ensure better dissolution in water. Although some PWID
also heat PH, it is done more out of tradition than out of need [6, 10].
2. Syringe rinsing. Because of its stickiness and viscosity, BTH requires multiple rinsing of the
syringe to prevent the needle from clogging if it is to be reused [13, 14].
3. Switching from venous to muscular injection sites. BTH appears to induce faster and more
severe venous scarring than PH, causing PWID to migrate to subcutaneous or intramuscu-
lar injection routes [15–17]
4. Acidity. Different heroin preparations vary widely by acidity [18]. BTH is believed to be
more acidic (pH ~ 2.8) than PH (pH ~ 4), with more acidic solutions showing reduced HIV
survivability in vitro [19]. However, the acidity of BTH has not been clearly quantified.
Fig 1. HIV prevalence and incidence in year 2000 vs. percentage of black tar heroin used in several major U.S. cities. Blue cities correspond to eastern US, green
cities to western US. Prevalence is depicted with circles and city names are centered around it. Squares denote 1996 incidence per 500 person-years in cities where it was
reported in Holmberg [9]. Prevalence and incidence in the same city are liked with a segment. Horizontal line represents 5% prevalence and incidence per 500 person
years. Incidence was scaled to 500 person-years to get numeric values within the same numeric range as the prevalence. HIV prevalence and incidence from Tempalski
et al. [8]; prevalence of black tar in the cities as reported in Ciccarone and Bourgois [6], from Domestic Monitoring Program 1991–1993. Drug Enforcement
Administration, U.S. Department of Justice.
https://doi.org/10.1371/journal.pone.0215042.g001
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Methods
In building a model we used the following mechanistic logic (Fig 2). A person can become
HIV infected when a number of HIV viruses enters his or her bloodstream. This number (viral
burden) is the product of the transmitted volume of liquid and viral load (concentration of
virus in a unit of liquid). The use of BTH or PH could modify viral burdens (viral loads multi-
plied by the transmitted volume of liquid) and the volume of transmitted liquid can be altered
by different injecting practices (e.g., high dead-space [HDS] syringes, sharing and rinsing).
Thus, individuals with the same viral load in their bodies can transmit different amounts of
virus depending on which heroin type they use and which injecting practices they employ.
Injecting practices in turn can be affected by cultural realities such as injecting norms, the
availability of replacement syringes, and the experience of the PWID involved. If one knows
the combination of risk factors and the effect of each factor on HIV transmission, one can
directly estimate the risk of HIV transmission. In reality, however, most of the evidence for the
impact of each of these factors on HIV risk is either qualitative or indirectly quantitative; thus,
we have to consider a number of simplifying assumptions based on available data.
Fig 2. A depiction of factors affecting HIV transmission through sharing syringes and the role of BTH/PH in the probability of
transmission. BTH/PH factors are overlaid with the oval.
https://doi.org/10.1371/journal.pone.0215042.g002
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In the following section we first describe an equation that links viral load and infectivity,
then translate each of the heroin factors into the change in viral burden. Next, we describe a
dynamic agent-based simulation model that combines all these factors together in the context
of injecting behaviors and the structure of injecting networks.
High and low dead space syringes
Zule et al. [20–22] and Bobashev and Zule [23] have shown that different syringe designs retain
different amount of blood that can be transferred to the next person who injects during shar-
ing. The syringes were classified as HDS or low dead space (LDS). Although the percentage of
HDS syringes currently used by PWID in the United States is small (around 5%), in the late
1980s the percentage was higher and was critical to supporting HIV transmission, especially in
high-risk populations that share syringes more than 10 times a year [23].
Reference transmission probability per exposure
Estimates of the probability of HIV transmission per exposure through receptive syringe shar-
ing range from 0.0051 to 0.0189, depending on the genetic subtype (B vs. E) [24–26]. We thus
use a reference value Pref of 0.008, which is similar to the ones in Patel et al. [27] and Bobashev
and Zule [23]. Because most of the estimates of the HIV risk were obtained from studies in
Thailand, we assume that PWID injected PH and used HDS syringes [20]. We assume that
most sharing occurred during the latent phase of HIV when the viral burden was around
10,000 copies per milliliter.
Viral burden and HIV probability by a single virion
In modeling the relationship between the viral burden and probability of transmission we used
a simple assumption that each virion has the same chance to start a disease. Thus, for a viral
burden of X copies of virus the probability of starting a disease P will be
P ¼ 1   ð1   p0Þ
X
ð1Þ
Which could be solved for p0 as
p0 ¼ 1   ð1   PÞ
1=X
ð2Þ
Where P is a probability of transmission associated with a viral burden X and p0 is a probability
of starting an infection by a single virion. The estimates of p0 are difficult to obtain directly but
could be evaluated from the following indirect considerations.
The volume of the shared blood and viral load is related to the type of syringe as described
in Zule et al. [21, 22]. If all shared syringes were rinsed once, the shared volume of blood
retained in the dead space would be around 0.0063ml resulting in 63 copies of the virion. For a
reference value of transmission probability Pref = 0.008 Eq (2) produces an estimate of p0 equal
to 1.3�10−4. If all syringes are rinsed twice, the volume of shared blood is 0.001ml (10 copies of
virion) and p0 equal to 8�10−4. We thus consider the estimate of p0 to be between 1.3�10−4 and
8�10−4.
Heroin type factors and viral burden
Heating the solution. Following Clatts et al.’s [12] observations of cooking times and tempera-
tures achieved in cookers and syringes in New York and Denver we considered that the solu-
tions on average reach a temperature of 65ºC (range 10–100) and it took about 6 seconds
(range 3–10) to reach the mean temperature. In that study, when heated to 66ºC in one sample
Heroin type and HIV
PLOS ONE | https://doi.org/10.1371/journal.pone.0215042 December 30, 2019 5 / 17
the virus was not recoverable after 10 seconds and in another sample, HIV was not recoverable
after 7 seconds when heated to 64ºC. Heating for less than 5 seconds had some effect but not
as strong as for heating over 5 seconds. It is notable, however, that extensive heating capable of
eliminating the virus does not happen all the time. In Denver where BTH is predominantly
used, about 20% of the time it was heated for less than 10 seconds and 40% of the time it did
not reach 66ºC. Thus, although protective, heating practices of BTH leave a window of oppor-
tunity for HIV transmission. We consider that when solutions of BTH are heated up to 66ºC
for over 10 seconds all viruses in the cooking equipment are inactivated. When heated liquid is
drawn into syringes the temperature drops by about 2ºC and the virus remaining in the syringe
might still survive. We assume that in those 40% of heating events when the temperature does
not reach 66ºC, virus survival is about 70%. PH is either mixed cold or heated for up to 15 sec-
onds, reaching 66ºC for over 5 seconds only 10% of the time. Thus, on average, when heating
the BTH solution, the survival rate of HIV virus in a syringe is around 10% (1–0.6�100%-
0.4�70%), compared to 90% (1–10%) when using PH solution heated to lower temperature.
Rinsing syringes. Most PWID rinse their syringes at least once if they expect to use them in
the future to prevent blood from clotting and clogging the needles. However, ethnographic
observations show that among BTH PWID an extra syringe rinse became the norm to addi-
tionally ensure that tar residuals do not clog future injections. Following [23, 28] we assume
that 0.084ml of liquid is left in an HDS syringe and that a 1ml syringe is rinsed with 0.5 ml of
water. Such a rinse reduces the amount of blood (and thus a number of virions) by a factor of
0.084/0.5 = 0.17. For LDS the reduction is much stronger and is around 0.002/0.5 = 0.004.
Acidity. In vitro experiments show that HIV-contaminated syringes are significantly less
likely to yield recoverable HIV when rinsed with citric acid solutions of pH at or less than 2.3
[19]. Although there is measured evidence of highly acidic solutions (depending on the type of
acidifier) in Europe [18], data on the acidity of BTH solutions is poorly known. Because BTH
is produced with acetic acid rather than acetic anhydride used in PH and because of other eth-
nographic observations BTH is suspected to be acidic [29]. We thus do not use any specific
HIV survival factor associated with acidity but note that our estimates are conservative (i.e.,
the effect of BTH on killing the virus is likely stronger because of the additional effect of
acidity).
Switching to non-intravenous injection sites. Using data from accidental needle-stick inju-
ries, the risk of HIV transmission following intramuscular poke is about 3 times less compared
to intravenous poke (0.002 vs. 0.006) [30, 31]. We assume from ethnographic observations that
on average about 25% of BTH injections are intramuscular or subcutaneous [32]. Rich et al.
[17] suggest that the probability of HIV transmission through subcutaneous injection is
negligible.
Simulation model
Agent-based models are microsimulations that reproduce individual behaviors in the context
of social networks and account for environmental and individual risks. In our model we simu-
late communities of PWID where individuals form injecting networks, can share syringes and
equipment, and transmit HIV from one person to another. These models allow detailed
description of injecting practices where HIV transmission risk is detangled into individual
components: sharing LDS syringes, sharing HDS syringes, and using PH versus BTH. Injecting
networks in our model have different sizes and connectivity and implement different injecting
norms (high and low probability of sharing). Flexibility in network structure allows us to imi-
tate a variety of areas (e.g. urban or rural) when more information about specific structures is
known. The worst-case scenario is set up to consider a highly dense network with high-risk
Heroin type and HIV
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behaviors of agents who use a large proportion of HDS syringes and inject PH. On the other
extreme, best case scenario, we consider a network with low level of sharing, use of LDS syrin-
ges, and BTH. The latter scenario leads to very low HIV incidence and illustrates an exemplary
success case of harm reduction. All other scenarios are between these two extremes. One such
scenario is when individuals switch from BTH to PH and less experienced individuals join the
network without knowledge of or adherence to the safe norms. Specific model setting assump-
tions are described below.
• The model focuses on the injecting pathway of HIV transmission, and sexual transmission is
considered only as a background force of infection, so each individual can become infected
with some small per act probability (0.001) scaled down by overall HIV prevalence (proba-
bility that sexual partner is HIV positive) and assuming a frequency of sexual activity of once
per week.
• In our model the agents were arranged in clustered networks (i.e., more intense syringe shar-
ing with the members of the same networks [buddies] and only occasional sharing with the
members of other networks [strangers]). These strangers represent the common pool of peo-
ple who inject drugs and facilitate the spread of HIV from one network to another. In our
model the structure of networks (i.e., who injects with whom) and within-network risk
behavior (i.e., how often agents share the syringe) was drawn at random from uniform distri-
butions. These networks were of different sizes: 20% very small (2 individuals), 70% medium
(3–8 individuals), and 10% large (9–20 individuals) with the average network size of eight as
was observed in a study of PWID in North Carolina. We considered for simplicity 64 net-
works that resulted in approximately 500 PWID.
• Each network could exhibit either high- or low-risk behavior norms. High versus low risk is
defined as higher rates of syringe-sharing episodes with strangers (1 vs. 12 times a year) and
within a network (e.g., 5 vs. 30 times a month). These parameters were estimated from the
supplementary data collected in two studies of PWID [28, 33].
• The role of different types of syringes and sharing practices in HIV transmission has been
discussed in a number of papers [23, 28, 33–35]. Most of the current injecting in the United
States occurs with LDS; however, for simulations related to the period 1992–2002 we assume
that about 10%-20% of syringes used by PWID were HDS, with higher rates in the south and
lower in the west [22, 33].
• We assume that only a fraction (e.g., 0.5) of the individuals in a network is present at a par-
ticular injecting episode. In simulation we only track injections that result in sharing syrin-
ges and do not consider injections alone.
• We consider a removal rate of 4%. Individuals may be removed because they die or stop
injecting. To keep the population stable and have the same denominator for incidence and
prevalence calculations, removed individuals are replaced with a similar but HIV-negative
individual on the basis that most new PWID are unlikely to have been exposed to the virus.
• Following Jaquez et al. [36], and Fiebig et al. [37] we assume that during the acute stage of
HIV infection the probability of transmission increases between 5 and 30 times. For simplic-
ity we use the value of a 10-fold increase.
• Our model does not consider a number of factors that affect the dynamics of HIV spread,
such as behavior change after becoming HIV positive, number of times syringes are reused,
and variation in viral load resulting from the use of antiretroviral therapy. These factors
affect the actual incidence and prevalence; however, for the purpose of examining the effects
Heroin type and HIV
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of heroin types, we assume that these factors vary in the same way between persons who use
PH and BTH, and the additional parameterization will increase model complexity without
critically impacting the results. A list of parameters is presented in Table 1.
Agent rules in the model. Agents in the model behave according to the following rules. At
each time step (corresponding to one day) agents in the network can probabilistically share
syringes. If sharing a syringe, the agent can choose to share with some “buddies” from the net-
work, and/or with a stranger. Recall that probability of sharing is compounded probability cor-
responding to the probability of injecting, and the probability of sharing given injection. The
probabilities are guided by the network type. If syringe is used after an HIV positive individual
it can transmit the virus to an HIV negative person who injects next. At each time step an
agent has a very small chance to contract HIV. This is a proxy for sexual transmission.
The model was programmed in NetLogo to provide interactive visualization of HIV trans-
mission in a community. A screenshot of the user interface is presented in Fig 3.
Table 1. Model parameters and their sources�. Annual and monthly rates in the model are recalculated to represent
daily probabilities. For example, the annual rate of 0.04 will result in the daily rate of 1-(1–0.04)1/365 = 0.00011.
Model Parameter Value Source
Initial HIV prevalence 0.05 (range 0.03–0.1) Experimental parameter
Number of networks 64 (range 1–200) Experimental parameter
Size of network cluster average 8 (range: 2–17) Bobashev and Zule, (2010)
[23]
Proportion of people in the cluster participating
in sharing
0.5 (range 0.3–0.8) Experimental parameter
Number of times sharing with buddies High risk: 30 per month (range
20–30) Low risk: 5 per month
(range 1–5)
Zule et al. (2002, 2009) [28,
33]
Number of times injecting with a stranger High risk: 10 times per year
(range 8–20) Low risk: 1 time per
year (range 0–2)
Experimental parameter
Removal rate (includes PWID HIV+ all-cause
mortality and PWID leaving the population [i.e.,
stop injecting]).
0.04 per year (range 0.02–0.06) Bailey et al. (2007) [38], De
et al. (2007) [39]
Risk of HIV transmission assuming HDS and
PH
0.008 per act (range 0.005–0.01) Hudgens et al. (2001, 2002)
[24, 25]
Risk multiplier for an acute stage of HIV
infection
10 (range 5–30) Jacquez et al.(1994) [36],
Fiebig et al. (2003) [37]
Risk multiplier for muscle injection 0.29 (range 0.02–0.06) Baggaley et al. (2006) [30]
Risk multiplier for heating 0.1 (range 0.05–0.15) Clatts et al. (1999) [12]
Risk multiplier for an extra rinse of an HDS
syringe
0.17 (range 0.1–0.2) Zule et al. (1997, 2018) [21,
22]
Risk multiplier for an extra rinse of an LDS
syringe
0.004 (range 0.002–0.008) Zule et al. (1997, 2018) [21,
22]
Rate of sexual HIV 10−4 per year (range 0.5�10−4–2
�10−4)
CDC (2017) [40] incidence
rates through sexual contacts
Note. SATH-CAP = Sexual Acquisition and Transmission of HIV Cooperative Agreement Program;
PWID = injecting drug user; BTH = black tar heroin, PH = powder heroin, HDS = high dead-space syringe;
LDS = low-dead-space syringe.
�“Experimental” parameter means that the value of the parameter varies between different geographic areas, cultures,
etc. For illustration purposes, we use a value that is considered reasonable. We use experimental parameters to design
“what if experiments” aimed at evaluating intervention strategies and conducting sensitivity analysis.
https://doi.org/10.1371/journal.pone.0215042.t001
Heroin type and HIV
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Simulation scenarios
In our analysis we considered the following scenarios:
Historic scenarios (Scenario A1, A2). These scenarios simulate what could potentially be
the historic setting east and west of the Mississippi River leading to observations described in
Ciccarone and Bourgois 2003 [6]:
Scenario A1. BTH + 20% HDS. This scenario mimics the western U.S. around the late
1980s through late 1990s. We assume that HDS syringes were used about 20% of the time even
with the early introduction of needle and syringe programs. We assume 100% of double rinses
and a starting HIV prevalence of 3%.
Scenario A2. PH + 20% HDS. This scenario mimics the eastern U.S. around the late 1980s
through late 1990s. Here we assume 60% chance of the second rinse and a starting HIV preva-
lence of 3%.
Futuristic scenario (Scenario B). A hypothetical scenario where PH becomes the dominant
form of heroin on the market across the United States, almost completely eliminating the use
of BTH.
Scenario B. PH + 97% LDS. This scenario assumes that LDS syringes will be used almost
exclusively to inject heroin, but occasionally HDS syringes are used. This could be true espe-
cially in areas where needle and syringe programs have limited reach.
Fig 3. A screenshot copy of the simulation model that describes the spread of HIV among PWID. Each injecting network can be high or low risk in terms of
frequency of syringe sharing (large pink or yellow squares) and using HDS or LDS syringes (small pink or yellow squares inside the large squares).
https://doi.org/10.1371/journal.pone.0215042.g003
Heroin type and HIV
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We computed incidence and prevalence trajectories for the simulated PWID population
and for high- and low-risk individuals under different combinations of parameter values. We
repeated simulations 1,000 times to obtain stable and smooth estimates of HIV prevalence and
incidence and uncertainty bounds. At each simulation we considered uncertainty in parameter
values (by drawing a value from a distribution), structural uncertainty (the number of net-
works and their structure), and internal stochasticity (randomness in behavior and disease
transmission).
We present the ranges of parameter values in Table 1. Because the actual parameter distri-
butions are not known we used the triangular distributions, which could be viewed as a sum of
two uniform distributions and are commonly used in simulations when the actual shape of the
distribution is not known. Because of the different nature of the input parameters we assume
their independence conditioned on whether an individual belongs to high or low risk network.
Findings
The role of BTH from a historical perspective (Scenarios A1 and A2). By considering commu-
nities with both 95% and 5% BTH use, our model was able to simulate HIV prevalence among
PWID in the western (3%-10%) and eastern United States (3%-20%), resulting in HIV rates
similar to those observed in Holmberg et al. [9] and Tempalski et al. [8]. In Fig 4 we present
simulated HIV prevalence in the western (scenario A1) and eastern (scenario A2) United
States for different proportions of high-risk networks. Simulated prevalence depends on the
proportions of high-risk networks, but that dependence is small in the areas with a high pro-
portion of BTH but quite substantial in the areas with PH.
The role of PH from the perspective of dominance in the illicit drug market (Scenario B).
Simulation results show a significant increase in the incidence and prevalence of HIV if PH
replaces BTH in a community. When simulating what could happen in the western United
States if PH became dominant there, we started with an average HIV prevalence of 5% and
20% of high-risk networks. In 10 years, the HIV prevalence increased to 8%, but the variability
of outcomes was high ranging from 4% to 17%. For high proportion (0.8) of high-risk net-
works the mean prevalence became 13% but the variability of the outcomes was even higher
ranging from 4% to 30% as illustrated in Fig 5.
Discussion
We have presented an agent-based simulation model that explores the effects of BTH and PH
on HIV prevalence and provides a plausible explanation for the differences in HIV prevalence
between metropolitan areas in the eastern and western United States. We have also shown that
if PH replaces BTH, the overall prevalence of HIV will slowly grow, primarily because there
will be local HIV outbreaks. These outbreaks are driven by local high-risk networks. Although
many experienced PWID over time have accepted certain safer injecting norms, newer, less
experienced PWID (e.g., migrant groups or PWID who are transitioning to heroin use from
prescription opioids) might be at the highest risk. The role of viral load, especially in the acute
phase of HIV, becomes additional fuel in high-risk networks with a lack of harm reduction
norms.
New populations of PWID who are joining high-risk networks might not be exposed to
harm reduction norms and will thus suffer. Because syringe exchange programs have been
shown to substantially reduce syringe sharing in injecting networks [38, 39, 46] our simula-
tions implicitly suggest that new pockets of HIV could emerge in areas where needle and
syringe programs are lacking and PWID routinely share their equipment. According to the
Foundation for AIDS Research [41] currently needle and syringe exchange programs remain
Heroin type and HIV
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illegal in 15 states (Mississippi, Alabama, Georgia, South Carolina, Florida in the South and
Texas, Oklahoma, Kansas, Nebraska, South Dakota, Iowa, Missouri, Arkansas, Wyoming, and
Idaho in the West). Even in states where needle and syringe programs are legal, rural areas
often lack access to them, and 93% of counties that are under high risk of HIV/HCV outbreak
do not have these programs [42]. The opioid crisis has brought some persons who use pills to
injection practices, whether by transitioning to injecting heroin [43] or through injecting opi-
oid pills, opening a specific opportunity for HIV outbreaks. In Scott County, Indiana, between
2014 and 2015, 181 people were diagnosed with HIV infection in a county that had seen only 5
diagnoses from 2004 to 2013. Eighty-eight of those diagnosed reported injection use of
extended-release oxymorphone which may be crushed, dissolved, and cooked [44, 45]. Our
simulations underscore that where the opioid/heroin epidemic is moving, so should be moving
interventions such as harm reduction and robust needle and syringe programs.
Although the initial motivation for our paper was the role of BTH in the early HIV epi-
demic, our conclusions have a much broader contemporary application internationally, for
example in Tajikistan and other countries where PH is used, needle and syringe programs rou-
tinely distribute HDS syringes and injecting norms (e.g., heating) are not preventing viral
transmission [21, 35].
Fig 4. Simulated HIV prevalence in eastern cities (5% BTH) and western cities (95% BTH) for different percent (10%, 20%, 50%, 80%) of high-risk networks. Bars
denote 95% range of simulated prevalences.
https://doi.org/10.1371/journal.pone.0215042.g004
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Sensitivity analysis and uncertainty assessment. The simulation model shows that the
results are naturally sensitive to the rates of sharing, initial prevalence, and risky behavior fac-
tors. The effects of these factors are more strongly pronounced in communities with no or little
of BTH. For example, to detangle a potential role of initial prevalence from the effects of BTH
we compared simulation results when both eastern and western models stared with the same
HIV prevalence. We considered 2 levels of HIV prevalence: 0.03 and 0.06. When simulating
western US (BTH presence 95%), HIV prevalence gain was about 0.01 for both 0.03 and 0.06
starting prevalences. In simulated eastern US (BTH presence 5%) prevalence rose by 0.09 and
0.13 respectively. In general, initial prevalence plays a stronger role in communities with
higher transmission potential (higher risk, use of BTH, use of HDS syringes). In communities
with low risk of HIV transmission the prevalence can decline due to the elevated mortality
among HIV positive individuals and low incidence. Similarly, the higher is the risk or preva-
lence, the higher is the effect of BTH. This leads to an important observation regarding public
Fig 5. An example of high variability of 100 possible HIV trajectories when a community of PWID with 80% of high-risk networks switches to PH. The mean
trajectory is shown in a thick solid black line. Variability of trajectories around the mean is high with a few trajectories (8 in this example) reaching a prevalence of over
25%. When HIV reaches a large high-risk cluster, the trajectory shows a fast increase in prevalence.
https://doi.org/10.1371/journal.pone.0215042.g005
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health interventions. The effect of BTH is strong in high-risk networks (i.e., networks where
agents share often within their network and with agents from the other networks [strangers]).
For low-risk networks the protective effect of BTH is negligible as seen in Fig 4. These results
offer a simple explanation that when a network is of low risk (an extreme situation is when no
sharing of any equipment occurs) then HIV is not spreading through injecting contacts
regardless of whether the network is using PH or BTH. When the level of sharing is high and is
more aggravated by unsafe sharing practices the protective role of BTH becomes more
evident.
Fig 5 illustrates the variability of the trajectories for a single scenario where for presentation
purposes we focused on the uncertainty associated with internal stochasticity. Additional vari-
ability of network structures, between-person variability in viral load, uncertainty in parameter
estimates, and structural uncertainty (i.e., different modelers would model and program the
same process differently) will increase the spread of possible outcomes. Adding these levels of
uncertainty results in coverage of the entire range of possibilities (i.e., in some simulations
some runs will produce prevalence of 1). Although such outcomes are very unlikely, for small
communities such as Scott County, IN, high-risk behavior could lead to very high incidence
and then prevalence.
Limitations and data considerations. As with most simulation studies, ours has a number of
common limitations. The utility of a simplified simulation modeling is limited because the
results are dependent on a number of simplifying assumptions. Some assumptions are techni-
cal (e.g., the structure of the injecting networks, homogeneous mixing within networks). Oth-
ers are critical to the description and understanding of the underlying process. For example, as
is mentioned in Tempalski et al. [8] there are many explanations for why HIV prevalence and
incidence among PWID is so different between U.S. regions. They mention “program efforts
to increase users’ access to clean syringes both through syringe exchange programs and phar-
macies; efforts to promote safer injection practices; effects of antiretroviral therapies on infec-
tivity of PWID, deaths from HIV not being matched by new infections; and possible changes
in risk networks and other social mixing patterns which vary from place to place. Differences
in HIV prevalence rates may also reflect differences in availability, accessibility and effective-
ness of HIV prevention and treatment programs across metropolitan areas.” More explana-
tions can be found in Ciccarone and Bourgois [6]. These are all important factors and could be
further considered in the models. For our simple exercise we rolled up many effects into a few
proxy factors. For example, access to clean syringes and effectiveness of prevention practices
are rolled into mechanistic risky behavior factors related to HIV transmission (i.e., how often
PWID share syringes with “buddies” and “strangers”). Access to HIV treatment programs
could be also represented by the level of risky behavior and the level of HIV viral load, which
could then be translated into the probability of transmission.
One critical limitation in our analysis is that we do not consider injections of other stimu-
lants (e.g. cocaine, and methamphetamine). A certain portion of HIV transmission among
PWID occurs among this population but the data to calibrate the difference between injecting
only heroin, heroin and other substances, and other substances but not heroin is problematic
and is beyond the scope of this study. Our historic estimates should be less certain in areas
where the majority of injection events were with cocaine and more certain in areas where the
majority of injection events were with opioids.
Sexual pathway is an important factor in HIV transmission but perhaps not as much
among persons who inject heroin. It is possible that there are certain individuals with high rate
of sexual contacts and risky injection which puts them at the elevated risk to receive and spread
HIV. Adding variability in sexual behaviors, will add variability to the background HIV preva-
lence. We assumed that sexual behaviors are not directly related to the type of heroin used,
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and although increased HIV prevalence could slightly amplify the incidence in BTH group,
the effect will not alter our conclusions.
While we can incorporate a broad variety of network structures our PWID network struc-
ture is of clustered small-world type with varying sizes of the local “buddy” neighborhood and
probabilities of small-world linkages. Zhong et al. [46] and Dombrowski et al. [47] suggested
that the distribution of the links is likely to be exponentially distributed. This could be a good
approximation when the links are considered to be of the same strength and are not dynami-
cally changing. Because links can have different weights depending on the strength of relation-
ships (e.g. buddy or stranger), accounting for that strength changes the nature of the networks
and the dynamics of HIV spread. Dynamic partnership changes can shift the infection dynam-
ics towards higher homogeneity i.e. over time a person will have higher number of encounters
with the others than when inferred from a network snapshot. Our network structure some-
what compensates for these factors by considering clustered small-world structure with links
of different strength. For example, individuals who belong to large high-risk buddy clusters
share syringes with many strangers (i.e. random individuals from the rest of the network) and
thus can become super-spreaders. Although these individuals might have a relatively small
number of buddies (compared to the total network size) they are connected to a large number
of buddy networks can facilitate HIV outbreaks. We thus keep the networks complex enough
to capture the major clustered buddy-stranger structure, but simple enough not to get tangled
in overly extensive parameterization.
In our model, we were specifically focused on a question that relates BTH and PH availabil-
ity and the role the related injecting practices can have in HIV transmission when keeping all
other factors the same. From this perspective, modeling studies allow an unparalleled opportu-
nity to explore “what if” scenarios that are not possible in the real world. Although simulation
results do not necessarily reproduce real-life processes, they do provide insight into the vari-
ability of HIV prevalence as a function of several additional risk factors, such as frequency of
syringe sharing, mixing patterns, and specific use practices. Another factor that justifies such
simplification is the lack of reliable data about these practices. Ethnographic research provides
in-depth insights into specific behavior, but it is very localized, while epidemiological studies
are broad but lack depth. Some measurements are just not ethical and not feasible to obtain.
For example, ethical concerns prohibit using controlled human experiments to estimate the
dependence of HIV transmission on viral load.
Because the aim of this research is to show the relative effect of different types of heroin, the
model is simple and focused to illustrate the main point. An interesting, emerging new source
of data is online blogs and help sites that can be mined for useful information. This informa-
tion provides complementary insights into what PWID (and not researchers) think is impor-
tant. Our future research will explore these new avenues.
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